NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead
On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading